Mainz Biomed N.V. Ordinary Shares
MYNZMainz Biomed N.V. is a biotechnology company focused on developing and commercializing innovative diagnostic solutions for early detection of cancer. The company specializes in non-invasive tests for gastrointestinal health, leveraging molecular biology and advanced technology to enhance early diagnosis and improve patient outcomes.
Company News
The article discusses two small-cap biotech companies with high-risk, high-potential investment opportunities: Mainz Biomed and NanoViricides. Both companies are developing innovative medical technologies but face significant financial challenges and are pre-revenue.
Mainz Biomed conducted a feasibility study on a non-invasive blood test for early pancreatic cancer detection, achieving 100% sensitivity and 95% specificity in identifying cancer and precancerous lesions across a 30-subject cohort.
Mainz Biomed reported a 33% increase in lab network revenue, a 30% decrease in operating loss, and an 18% decrease in net loss in 2024. The company made progress with strategic partnerships and its next-generation colorectal cancer screening product.
Mainz Biomed, a molecular genetics diagnostic company, is committed to combating colorectal cancer (CRC) by advancing diagnostic solutions for early detection. The company's flagship product, ColoAlert, and its next-generation screening method, which combines mRNA biomarkers, the FIT test, and a proprietary AI algorithm, demonstrate high sensitiv...
Mainz Biomed, a molecular genetics diagnostic company, has partnered with labor team, a Swiss diagnostic laboratory, to introduce its DNA-based colorectal cancer screening test, ColoAlert, to the Swiss market. The partnership aims to increase participation in early detection and prevention of colorectal cancer in Switzerland.
